- Home
- ORCL vs ABBV Comparison
ORCL vs ABBV Comparison
Compare ORCL & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORCL
- ABBV
- Stock Information
- Founded
- ORCL 1977
- ABBV 2012
- Country
- ORCL United States
- ABBV United States
- Employees
- ORCL N/A
- ABBV N/A
- Industry
- ORCL Computer Software: Prepackaged Software
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- ORCL Technology
- ABBV Health Care
- Exchange
- ORCL Nasdaq
- ABBV Nasdaq
- Market Cap
- ORCL 390.8B
- ABBV 348.0B
- IPO Year
- ORCL 1986
- ABBV N/A
- Fundamental
- Price
- ORCL $190.78
- ABBV $167.74
- Analyst Decision
- ORCL Buy
- ABBV Strong Buy
- Analyst Count
- ORCL 27
- ABBV 21
- Target Price
- ORCL $175.13
- ABBV $206.00
- AVG Volume (30 Days)
- ORCL 6.3M
- ABBV 7.3M
- Earning Date
- ORCL 12-09-2024
- ABBV 10-30-2024
- Dividend Yield
- ORCL 0.84%
- ABBV 3.92%
- EPS Growth
- ORCL 15.20
- ABBV N/A
- EPS
- ORCL 3.88
- ABBV 2.87
- Revenue
- ORCL $53,815,000,000.00
- ABBV $55,533,000,000.00
- Revenue This Year
- ORCL $11.84
- ABBV $5.27
- Revenue Next Year
- ORCL $12.02
- ABBV $5.65
- P/E Ratio
- ORCL $49.16
- ABBV $58.45
- Revenue Growth
- ORCL 5.60
- ABBV 0.72
- 52 Week Low
- ORCL $99.26
- ABBV $137.65
- 52 Week High
- ORCL $191.77
- ABBV $207.32
- Technical
- Relative Strength Index (RSI)
- ORCL 68.26
- ABBV 27.67
- Support Level
- ORCL $182.33
- ABBV $163.81
- Resistance Level
- ORCL $191.77
- ABBV $206.15
- Average True Range (ATR)
- ORCL 3.50
- ABBV 3.66
- MACD
- ORCL 0.43
- ABBV -2.89
- Stochastic Oscillator
- ORCL 95.70
- ABBV 9.28
About ORCL Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).